Health Trials

HRR Deficiency

3

Review clinical trials related to HRR Deficiency. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors

This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN608 as monotherapy in adult patients with advanced solid tumors

Participants needed: 105
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdUpdated: Jul 28, 2025Locations: 2
Eligibility criteria

Having signed the written Informed Consent Form (ICF); [+8]

Previous or current use of Poly (ADP) ribose glycohydrolase (PARG) inhibitors; [+9]

Read more
Status: Recruiting

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors

Participants needed: 30
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdUpdated: Jul 20, 2025Locations: 2
Eligibility criteria

Having signed the written Informed Consent Form (ICF); [+8]

Previous or current use of POLQ inhibitors; [+8]

Read more
Status: Recruiting

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).

Participants needed: 144
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Eisbach Bio GmbHUpdated: Sep 19, 2024Locations: 1
Eligibility criteria

Recurrent locally advanced or metastatic solid tumors [+6]

History or evidence of any clinically relevant gastrointestinal disease [+3]

Read more